Phase 3 trials of Russian COVID-19 vaccine to start in Philippines in October

Published: 13 August, 2020 13:44 IST | ANI | Mumbai

Russian President Vladimir Putin endorsed the vaccine, saying it has passed all necessary checks

This file handout picture provided by the Russian Direct Investment Fund shows the vaccine against the COVID-19 coronavirus disease, developed by the Gamaleya Research Institute of Epidemiology and Microbiology. Pic/ Russian Direct Investment Fund / AFP
This file handout picture provided by the Russian Direct Investment Fund shows the vaccine against the COVID-19 coronavirus disease, developed by the Gamaleya Research Institute of Epidemiology and Microbiology. Pic/ Russian Direct Investment Fund / AFP

Phase 3 clinical trials of the Russian COVID-19 vaccine will be held in the Philippines from October to March, Philippine presidential spokesperson Harry Roque said on Thursday. The spokesperson added, as cited by the Inquirer newspaper, that the Russian government would fund the trials, which usually envisage vaccinating thousands of patients to test its efficiency and safety.

Phase 3 trials would be carried out by Russia and the Philippines during the same period, according to Roque. The spokesperson said that Manila expects the Philippines' Food and Drug Administration to approve the Russian-made vaccine by April 2021.

The vaccine, developed by the Gamaleya Research institute, was named Sputnik V and registered on Tuesday. Russian President Vladimir Putin endorsed the vaccine, saying it has passed all necessary checks.

Manila was one of the first to express interest in Sputnik V and readiness to cooperate with Moscow on clinical trials and production, while Philippine President Rodrigo Duterte has even volunteered to take the inoculation in public.

Keep scrolling to read more news

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Sign up for all the latest news, top galleries and trending videos from Mid-day.com

Subscribe
loading image
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK